Primary and Secondary Outcomes From a Phase I Study Comparing the Respiratory Effects of Buprenorphine Buccal Film and Oral Oxycodone Hydrochloride Administration

Primary and Secondary Outcomes From a Phase I Study Comparing the Respiratory Effects of Buprenorphine Buccal Film and Oral Oxycodone Hydrochloride Administration

Lynn Webster, MD, Executive Vice President of Scientific Affairs, recently presented his poster titled “A Review of the Primary and Secondary Outcomes From a Phase I Study Comparing the Respiratory Effects of Buprenorphine Buccal Film and Oral Oxycodone Hydrochloride Administration.”

A phase 1 randomized, double-blind, placebo-controlled, double-dummy crossover study was conducted to compare the effects of Buprenorphine Buccal Film (BBF) and oxycodone immediate-release (IR). The study focused on respiratory drive, pharmacokinetics, oxygen saturation, and pupillary-constricting effects. The review covers previously published data from the study, which included healthy men and women who self-identified as recreational opioid users but were not currently dependent on opioids.

You can watch the presentation or read the article below.

Read the Article
Lynn Webster, MD

Lynn Webster, MD

Dr. Webster is an internationally recognized clinical research expert in pain and addiction medicine. He has participated as an Investigator in hundreds of clinical trials and has authored more than 300 peer reviewed articles. He is board certified in anesthesiology, pain medicine and addiction medicine. He is the former co-founder of Lifetree Medical as well as an editor of Pain Medicine. Dr. Webster also serves as a peer reviewer of several professional journals and is a National Institute of Health grant reviewer. He has significant expertise in clinical research with a focus in experimental and human pain models, human abuse potential studies as well as assessing drugs’ effects on respiratory depression.

Interested in conducting a clinical trial?

Contact Us